Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Biophytis ( (BPTSY) ).
On November 13, 2025, Biophytis announced that all resolutions proposed during their Combined General Meeting were approved, including the financial statements for the fiscal year 2024. This approval, achieved with a shareholder quorum of nearly 31%, reflects strong shareholder support and is pivotal for the company’s strategic initiatives in developing transformative therapies for age-related diseases.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Underperform.
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. Their lead drug candidate, BIO101, is aimed at treating muscular diseases like sarcopenia and metabolic disorders such as obesity. The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. It is listed on Euronext Growth Paris and the OTC market.
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.15M
Find detailed analytics on BPTSY stock on TipRanks’ Stock Analysis page.